In line with a trend for big life science firms to divest non-core operations, medtech giant Baxter International (NYSE: BAX) is to sell off its biopharma manuf 10 May 2023
A bumper month of M&A activity in March gave way to one with just three acquisitions in April—albeit two of those were multi-billion dollar deals. 9 May 2023
Californian biopharmaceutical firm Amgen as reported a 2% drop in revenues in the first quarter, to $6.1 billion, a reflection of falling sales of COVID-19 ther 28 April 2023
The long-rumored acquisition of US biotech Seagen was finally announced in March, albeit it was not long-time suitor Merck & Co behind the deal, but rather fell 4 April 2023
As part of its reorganization around key therapy areas of oncology and immunology, Belgian biotech company Galapagos is hiving off certain research functions. 31 March 2023
A new oncology-focused spinout will be launched by Citius Pharmaceuticals, with the goal of developing the immuno-oncology asset I/ONTAK. 31 March 2023